The goals of the Phase I portion of the cordycepin study are to establish the recommended dose in the target population, determine drug-related dose-limiting toxicities, and assess pharmacokinetics.
Under the agreement, Truly Natural will market Bioponic’s key product lines as part of the company’s national product roll-out strategy. Effective July 1, 2008, Truly Natural will begin
Under the terms of the agreement, Roche will fully acquire Mirus for $125 million and will maintain an RNAi research site in Madison. Mirus’s transfection reagents business will
The US National Institute of Allergy and Infectious Diseases (NIAID) said that it had scrapped the trial because of uncertainties over the underlying science. According to NIAID, the
The patent infringement action was filed at the US District Court of California requesting, among others, an order that the date of approval of Impax’s ANDA be not
The selling stockholders plan to grant to the underwriters an option to purchase from them an additional 699,615 shares to cover over-allotments, if any. CardioNet will not be
Together, the patents expected to be issued based on these notices of allowance, with anticipated terms until 2025 and 2024, respectively, would provide strong and broad protection for
Under the terms of the promotion agreement, Santarus paid Depomed a $12 million upfront fee, and based on the achievement of specified levels of annual Glumetza net product
The company has also announced that the FDA clearance includes its second generation eSensor XT-8 molecular diagnostics platform. Osmetech’s eSensor warfarin sensitivity test detects the three genetic markers
The patent covers Rexahn’s anticancer candidate, RX-0183 and related compounds, and are targeted, small molecule quinazoline analogues that inhibit key molecules such as c-Fos and Akt proteins. Akt
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.